Back to News Page
Source: TechPoint
TechPoint covers Boomerang Ventures’ strategic pre-seed investment in IMPOWER HEALTH and the appointment of healthcare executive Trent McCracken as CEO. The company’s patented software transforms everyday treadmills into lab-grade gait diagnostic platforms, delivering objective, reimbursable mobility insights for rehabilitation, performance, and preventive care.
Source: Business Insider
Business Insider highlights Boomerang Ventures’ strategic pre-seed investment in IMPOWER HEALTH and the appointment of Trent McCracken as CEO. IMPOWER HEALTH is redefining mobility measurement by transforming everyday treadmills into clinical-grade gait diagnostic tools, delivering objective, reimbursable insights without wearables or cameras.
Source: AP News
AP News reports that Boomerang Ventures has led a strategic pre-seed investment in IMPOWER HEALTH and appointed Trent McCracken as CEO. The company’s patented platform transforms standard treadmills into lab-grade gait diagnostic tools, enabling objective, reimbursable mobility insights across rehabilitation, performance, and preventive health settings.
Source: Indianapolis Business Journal
IBJ’s The Deal reports that Boomerang Ventures led a $750,000 pre-seed investment round for Impower Health Inc., an Omaha-based health-tech startup. Impower’s treadmill-based gait tracking technology enables lab-grade mobility analysis for rehab clinics and gyms, helping support measurable improvements in mobility and movement health.
Boomerang Ventures has led a strategic pre-seed investment in IMPOWER HEALTH, a mobility health startup transforming treadmills into clinical-grade gait diagnostics platforms. The Omaha-based company also appointed Trent McCracken as CEO as it advances commercialization and OEM partnerships. IMPOWER HEALTH’s technology captures objective, reimbursable gait variability data across rehabilitation and performance-focused fitness settings, positioning mobility as a measurable clinical biomarker.
Source: Inside INdiana Business
Indianapolis-based startup HabitHalo is helping people quit vaping through its innovative RipLok device, which combines smart hardware and personalized technology to gradually reduce vape use. Founded by IU graduate Phil Tran, HabitHalo is transforming personal experience into a mission-driven solution for healthier habits.
Source: Startup Health
SynchNeuro has secured seed-stage support from Boomerang Ventures to advance its brain-based, non-invasive continuous glucose monitoring technology. Using EEG-derived signals decoded by machine learning, the company is developing a wearable “Cardiometabolic Advisor” that tracks blood glucose and metabolic indicators without needles. The investment accelerates development and moves the device closer to broad market adoption.
Source: CityBiz
SynchNeuro, a Philadelphia-based health-technology startup founded by neurosurgeon Dr. Casey Halpern, has secured seed funding from Boomerang Ventures. The company is developing a non-invasive EEG-based platform that decodes brain-signal activity into metabolic insights, aiming to support individuals with prediabetes and early-stage Type 2 diabetes. The investment will help expand operations and accelerate product development.
Source: Indianapolis Business Journal
Boomerang Ventures has taken the lead in a $3 million seed round for SynchNeuro Inc., a Philadelphia-based health tech startup developing a wearable sensor that translates brainwave activity into real-time health insights. As part of the investment, Boomerang Founder and Managing Partner Oscar Moralez has joined the company’s board, strengthening the partnership as SynchNeuro advances its technology to monitor blood sugar and other critical health metrics.
Source: Tech Point
Boomerang Ventures is backing SynchNeuro’s pioneering effort to build the world’s first brain-based, non-invasive continuous glucose monitor. Using EEG-derived brainwave signals decoded by machine learning, SynchNeuro aims to track blood glucose and cardiometabolic indicators via a discreet wearable placed behind the ear. This seed-stage investment will help speed development of the “Cardiometabolic Advisor” system and bring proactive, needle-free monitoring closer to mass market.
Back to News Page
